Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: Results from Kochi RYOMA study  by Kubo, Toru et al.
JO
G
o
c
K
T
T
Y
Y
D
R
A
0
dournal of Cardiology (2010) 56, 314—319
avai lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / j j cc
riginal article
ender-speciﬁc differences in the clinical features
f hypertrophic cardiomyopathy in a
ommunity-based Japanese population: Results from
ochi RYOMA study
oru Kubo (MD), Hiroaki Kitaoka (MD, FJCC) ∗, Makoto Okawa (MD),
akayoshi Hirota (MD), Kayo Hayato (MD), Naohito Yamasaki (MD),
oshihisa Matsumura (MD, FJCC), Toshikazu Yabe (MD),
oshinori L. Doi (MD, FJCC)
epartment of Medicine and Geriatrics, Kochi Medical School, Oko-cho, Nankoku-shi, Kochi 783-8505, Japan
eceived 6 May 2010; received in revised form 1 July 2010; accepted 2 July 2010
vailable online 16 August 2010
KEYWORDS
Hypertrophic
cardiomyopathy;
Gender
Summary
Objectives: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with a broad
spectrum of clinical features. Although gender may be one of the important modifying factors
in HCM, there has been little information on gender differences.
Methods: We investigated gender-speciﬁc differences in the clinical features of HCM in a
community-based Japanese population. We established cardiomyopathy registration in Kochi
Prefecture named Kochi RYOMA study consisting of 9 hospitals as an unselected regional
Japanese population.
Results: 261 patients with diagnosis of HCM were registered. At registration, 88 patients (34%)
were women. Female patients were more frequently diagnosed as having HCM at ≥65 years
(41% versus 27%) and had a higher ratio of familial HCM (35% versus 19%). More female patients
had diagnosis of HCM due to cardiac symptoms (64% versus 40%) and were symptomatic both
at diagnosis and at registration. Although the prevalence of atrial ﬁbrillation was not differ-
ent between males and females, embolic events occurred less frequently in female patients
at registration than in male patients (2% versus 10%). In female patients, there were more
obstructive HCM patients and fewer patients with apical HCM. Left ventricular and left atrial
diameters were smaller and fractional shortening was higher in females than in males.
∗ Corresponding author. Tel.: +81 88 880 2352; fax: +81 88 880 2349.
E-mail address: kitaokah@kochi-u.ac.jp (H. Kitaoka).
914-5087/$ — see front matter © 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusions: The manifestations of HCM in unselected Japanese patients differed in men and
women, which suggest that hormonal, social, and genetic factors may inﬂuence the clinical
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four patients (25%) had proven familial HCM and 45 patients
(17%) had a family history of sudden death. At registra-presentation of HCM.
© 2010 Japanese College of C
Introduction
Hypertrophic cardiomyopathy (HCM) is a primary and geneti-
cally transmitted myocardial disorder with a broad spectrum
of morphologic features and clinical presentations [1—6].
The cardiac phenotype of HCM shows marked diversity in the
degree and pattern of left ventricular hypertrophy (LVH),
age of onset, and clinical course. This phenotypic hetero-
geneity can be established by genetic factors, including
private disease-causing mutations and polymorphisms, and
by environmental factors. Gender has been hypothesized
to be one of the important modifying factors in HCM as
gender-speciﬁc differences have proved to exist in acquired
cardiovascular diseases, including coronary heart disease,
valvular heart disease, heart failure, atrial ﬁbrillation, and
stroke [7—10]. However, there have been few studies in
which gender-related differences in the clinical features of
HCM in Japan were investigated. Here, we present gender
differences from the results of baseline characteristics at
registration of the Kochi RYOMA (RegistrY Of MyocArdial dis-
eases) study as a community-based and unselected regional
Japanese population [11].
Methods
Subjects
We established the Kochi Cardiomyopathy Network consist-
ing of 9 hospitals serving as primary, secondary, and tertiary
referral medical centers for cardiovascular patients in Kochi
Prefecture, Japan with 800 000 inhabitants, and 261 patients
with a diagnosis of HCM were registered between 2004 and
2008. The diagnosis of HCM was based on two-dimensional
(2D) echocardiographic demonstration of an unexplained
LVH. Informed consent was obtained from all subjects or
their families in accordance with the Ethics Committee on
Medical Research of Kochi Medical School.
Clinical evaluation
Evaluation of patients included medical history, clinical
examination, 12-lead electrocardiography (ECG), M-mode,
2D, and Doppler echocardiography, and ambulatory 24-
h Holter ECG analysis. The severity and distribution of
LVH were assessed in the parasternal short axis plane
at mitral valve and papilliary muscle levels. Left ven-
tricular end-diastolic diameter (LVEDD) and end-systolic
diameter (LVESD) were measured from M-mode and 2D
images obtained from parasternal long-axis views, and
fractional shortening (%FS = (LVEDD− LVESD)/LVEDD× 100)
was calculated. LV outﬂow tract gradient was calculated
from continuous-wave Doppler using the simpliﬁed Bernoulli
equation.
t
c
i
ﬁ
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Based on morphologic and hemodynamic assessments by
chocardiography, we divided the patients into the follow-
ng ﬁve groups: (1) hypertrophic obstructive cardiomyopathy
HOCM), deﬁned as presence of basal LV outﬂow tract
bstruction (gradient ≥30mmHg at rest); (2) midventricular
bstruction (MVO), deﬁned as presence of systolic LV cav-
ty obliteration at the midventricle creating midventricular
bstruction with a peak systolic gradient ≥30mmHg at rest;
3) dilated phase of HCM (D-HCM), deﬁned as LV systolic dys-
unction of global ejection fraction (EF) < 50% (Global EF was
etermined from apical two- and four-chamber views. Con-
omitant coronary artery disease was excluded by coronary
ngiography and/or myocardial scintigraphy.); (4) apical
CM, deﬁned as hypertrophy conﬁned to the LV apex; (5)
thers: HCM without obstruction other than D-HCM and api-
al HCM.
History of major morbid events including (1) hospital-
zation for heart failure and (2) embolic complications,
ncluding stroke and other systemic embolic events, which
ccurred as a result of probable or proven embolism was
hecked at registration.
ata analysis
tatistical analysis was performed using SPSS (version 14.0)
tatistical software (SPSS Inc., Chicago, IL, USA). All data
re expressed as mean± SD (range) or frequency (percent-
ge). Differences in continuous variables were assessed
sing Student’s t test. Pearson’s chi-square test was used for
omparisons between non-continuous variables, and Fisher’s
xact test was used when expected frequency was lower
han 5. Statistical signiﬁcance was deﬁned by p≤ 0.05.
esults
linical characteristics at registration
he clinical characteristics of the 261 patients with HCM
t registration are as follows. The ages at registration
nd at diagnosis were 64± 14 (range: 9—88) and 57± 15
range: 6—87) years, respectively, and 88 patients (34%)
ere women. About half (48%) of the patients were diag-
osed because of symptoms and 136 patients (52%) were
valuated because of incidental ﬁndings, including ECG
bnormalities and systolic murmur, and family screening.
resence of symptoms was seen in 171 patients (66%) at
iagnosis and in 165 patients (63%) at registration. Sixty-ion, 74 patients (28%) had documentation of paroxysmal or
hronic atrial ﬁbrillation (AF). Three patients received an
mplantable cardioverter-deﬁbrillator (two for ventricular
brillation and one for sustained ventricular tachycardia).
f the 261 patients, there were 40 patients in the HOCM
316 T. Kubo et al.
Table 1 Clinical characteristics of HCM patients.
Male patients (n = 173) Female patients (n = 88) p
Age at registration, years 63± 13 64± 16 0.612
Age at diagnosis, years 56± 14 57± 18 0.464
Reason for diagnosis: symptoms, n (%) 69 (40%) 56 (64%) <0.001
Symptoms at diagnosis, n (%)
Presence of symptoms 99 (57%) 72 (82%) <0.001
Chest pain 48 (28%) 31 (35%) 0.214
Palpitation 38 (22%) 35 (40%) 0.002
Syncope 7 (4%) 9 (10%) 0.049
NYHA functional class
I 118 (68%) 44 (50%) 0.004
II 49 (28%) 39 (44%) 0.010
III and IV 6 (3%) 5 (6%) 0.516
Symptoms at registration, n (%)
Presence of symptoms 99 (57%) 66 (75%) 0.005
Chest pain 46 (27%) 25 (28%) 0.755
Palpitation 34 (20%) 27 (31%) 0.047
Syncope 7 (4%) 4 (5%) 1.000
NYHA functional class
I 106 (61%) 40 (45%) 0.015
II 56 (32%) 41 (47%) 0.025
III and IV 11 (6%) 7 (7%) 0.630
Presence of AF at registration, n (%) 51 (29%) 23 (26%) 0.571
History of embolic complications, n (%) 17 (10%) 2 (2%) 0.026
History of heart failure admission, n (%) 18 (10%) 11 (13%) 0.611
Family history of HCM, n (%) 33 (19%) 31 (35%) 0.004
Family history of sudden death, n (%) 27 (16%) 18 (20%) 0.327
Pacemaker implantation, n (%) 10 (6%) 2 (2%) 0.348
ICD implantation, n (%) 3 (2%) 0 (0%) 0.553
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roup, 7 patients in the MVO group, 10 patients in the D-
CM group, 46 patients in the apical HCM group, and 158
atients in the other group.
ender-speciﬁc differences
linical characteristics of female patients at registration
n comparison with those of male patients are shown in
able 1. Age at diagnosis was not different. However, the
eak age distributions at diagnosis seemed to be older in
emale patients than in males (Figs. 1 and 2). Fig. 3 shows
he prevalence of patients with age at diagnosis ≥65 years.
emale patients were more frequently diagnosed as having
CM at ≥65 years (p = 0.018).
Female patients had a signiﬁcantly higher ratio of proven
amilial HCM with at least one relative who had an unequiv-
cal diagnosis (p = 0.004). On the other hand, frequency of
amily history of sudden death was not signiﬁcantly different
etween the two genders.
Table 1 also shows symptoms and clinical complications.ore female patients had diagnosis of HCM due to cardiac
ymptoms than did male patients (p < 0.001). The presence
f symptoms both at diagnosis and at registration was higher
n female patients (palpitation and dyspnea as judged by
YHA functional class). Although the prevalence of AF was
o
t
i
b
sAF, atrial ﬁbrillation; ICD, implantable cardioverter-deﬁbrillator.
ot different between males and females, embolic events
ccurred less frequently in female patients at registration
han in male patients (p = 0.026). On the other hand, severe
eart failure requiring hospitalization occurred equally in
he two groups. Prevalence of pacemaker or implantable
ardioverter-deﬁbrillator implantation was not different.
Table 2 shows echocardiographic data at registration. In
emale patients, there were more HOCM patients and fewer
atients with apical HCM. LVEDD and left atrial diameter
ere smaller and %FS was higher in females than in males.
iscussion
CM is a primary myocardial disorder with heterogeneous
linical and morphologic features [1—6]. The diverse clini-
al phenotype suggests the existence of some factors that
odify disease presentation, and gender has been hypoth-
sized to be one of the important factors affecting clinical
anifestations. However, there has been little information
n gender differences in Japanese patients with HCM. In
his study, we investigated the gender-related differences
n a community-based Japanese HCM population based on
aseline characteristics at registration of the Kochi RYOMA
tudy.
Gender differences in HCM 317
Figure 1 Age at diagnosis
Figure 2 Age distribution at diagnosis. Box plots with median
age.
Figure 3 Percentage of patients with age at diagnosis ≥65
years.
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ifferences in prevalence of HCM by gender
CM is usually caused by mutations in the genes that encode
arcomere contractile proteins and genetically transmitted
ith a Mendelian autosomal dominant pattern of inheritance
1—4]. Therefore, males and females are expected to be
qually represented. However, the present study showed
2:1 predominance of male patients, which is similar to
he prevalence in previous studies in Western countries and
apan [10,12—16]. Some possible explanations for this dif-
erence in prevalence of HCM by gender are (1) different
edical screening system, (2) clinician bias, and (3) dif-
erent penetrance (probability that a person who has the
enotype will manifest the character) between the two gen-
ers. First, in Japan, ECGs are routinely required of all
orkers after the age of 40 years, even in the absence
f recognized medical problems. If the ECG is abnormal,
he employee is referred for further cardiovascular evalua-
ion. Considering the higher rate of employment in men, the
evel of awareness regarding HCM may be higher in males.
econd, clinicians may pay less attention to early clinical
igns in women because cardiac diseases such as coronary
rtery disease and hypertension are usually predominant
n males in clinical practice. In addition to these explana-
ions, women may have some mechanisms, such as genetic
modiﬁer genes on the sex chromosome) and sexual hor-
onal factors, preventing the development of hypertrophy
nd resulting in later onset of disease in female patients, as
entioned in the following, which may be related to under-
epresentation of women with HCM [17]. In fact, Charron et
l. evaluated patients with HCM in a French genotype popu-
ation and found that penetrance was greater in males than
n females (77% versus 58%, age-adjusted odds ratio: 3.98,
I 95%: 1.34—11.48) [7].elayed diagnosis in women
n this study, female patients were more frequently diag-
osed as having HCM at ≥65 years of age, although mean age
318 T. Kubo et al.
Table 2 Echocardiographic data at registration.
Male patients (n = 173) Female patients (n = 88) p
Subtype, n (%)
HOCM 16 (9%) 24 (27%) <0.001
MVO 5 (3%) 2 (2%) 1.000
D-HCM 7 (4%) 3 (3%) 1.000
Apical HCM 43 (25%) 5 (6%) <0.001
Others 102 (59%) 54 (61%) 0.708
Maximum LV wall thickness, mm 19.2± 4.1 18.8± 3.7 0.446
LV end-diastolic diameter, mm 47.8± 5.7 43.3± 5.9 <0.001
Fractional shortening, % 40.0± 8.5 42.8± 8.7 0.013
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pLeft atrial diameter, mm 45.2± 7.
HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstruct
phase of hypertrophic cardiomyopathy; LV, left ventricular.
t diagnosis was not different between the two genders. Sev-
ral studies have shown that women with HCM had delayed
nset of symptoms and clinical identiﬁcation compared
ith men [7,10,18,19]. These data indicate that endocrine
ssociated with female gender may delay the develop-
ent of hypertrophy. Indeed, estrogen through estrogen
eceptor activation might modulate hypertrophic signaling
n females, since estrogen treatment reduced myocardial
ypertrophy in animal models [20].
ender differences in clinical manifestations
ompared to male patients, female patients were more
requently diagnosed as having HCM by virtue of cardiac
ymptoms and were more symptomatic both at diagnosis
nd at registration, particularly palpitation and dyspnea, in
ur study. Olivotto et al. also reported that female patients
ere less often diagnosed fortuitously by routine medical
xamination and were more symptomatic [10]. Although
he reasons for the gender differences in symptoms are
nknown, medical screening system and clinician bias, as
entioned above, may be related to the different degrees
f symptoms. That is, female patients may have less oppor-
unity to be diagnosed with HCM before the development
f symptoms. For clinical complications at registration, the
revalences of AF and hospitalization for heart failure were
ot different between males and females. On the other
and, embolic events occurred less frequently in female
atients than in male patients in our study. Olivotto et
l. showed in their longitudinal study that female gender
as independently associated with risk of symptom pro-
ression to NYHA functional classes III/IV or death from
eart failure or stroke compared with male gender [10]. We
eed to have follow-up data from the Kochi RYOMA study
s a Japanese cohort to clarify whether female gender is
igniﬁcantly associated with HCM-relatedmortality andmor-
idity.
In echocardiographic data at registration in this study,
here were several differences between the two genders.
pical HCM was predominant in males, as previously shown
21—26]. On the other hand, LV outﬂow obstruction was sig-
iﬁcantly more frequent in females, which in turn could
e related to smaller LV size and higher LV contractil-
ty. Although the mechanism of LV outﬂow tract gradient
(
q
H
T
f43.0± 8.1 0.029
ardiomyopathy; MVO, midventricular obstruction; D-HCM, dilated
nduction is complex and the mitral valve apparatus also
ontributes to obstruction by systolic anterior motion of the
itral leaﬂet, Dimitrow et al. reported that the most potent
redictor of LV outﬂow tract obstruction was LV end-systolic
imension in females with HCM [8]. The more symptomatic
tatus in female patients may be in part due to the higher
revalence of LV outﬂow obstruction.
In this cohort, interestingly, family history of HCM was
igniﬁcantly more frequent in female patients. This reason
ight be that in males there were more patients with apical
CM in whom family history of HCM was recognized to be
are. However, analyzing the data after apical HCM patients
ere excluded in this cohort, family history of HCM was still
igniﬁcantly seen more in female patients (37% versus 25%;
= 0.047).
imitations
e provided descriptions of gender differences based on
aseline characteristics at registration in a community-
ased Japanese population. Clinical complications including
F, embolic events, and hospitalization for heart failure
ere evaluated retrospectively. Therefore, further stud-
es on the gender-related differences of clinical course in
atients with HCM from the follow-up data in Kochi RYOMA
tudy as a prospectively assembled patient cohort in Japan
re needed because data of gender differences with regard
o clinical outcome are important for deciding the treatment
trategies.
onclusions
n our unselected regional registry, manifestations of HCM
n Japanese patients differed in men and women: female
atients were more frequently diagnosed at advanced age
≥65 years) and were more symptomatic, had less fre-
uent embolic events and more frequent family history of
CM, and presented LV outﬂow obstruction more frequently.
hese differences suggest that hormonal, social, and genetic
actors may inﬂuence the clinical presentation of HCM.
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